SaaS Metrics
Formulary Barriers, Cost Scrutiny
Formulary
AI Synthesis & Market Narrative
Rigid formulary systems, particularly in major pharmacy benefit managers, are emerging as significant market access barriers for new drugs, leading to legal challenges and intensifying scrutiny on Medicare drug costs.
Correlated Linguistic Patterns
["Medicare drug costs"
"rigid formulary system"
"neffy coverage decision"
"market access"]
Driving Media Context
Omeros Corporation Q2 2026 Earnings Call Summary
Moby summary of Omeros Corporation's Q2 2026 earnings call
Journey Medical Corporation Q2 2026 Earnings Call Summary
Moby summary of Journey Medical Corporation's Q2 2026 earnings call
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class Action - Contact the Firm
Allegations focus on ARS Pharmaceuticals' alleged failure to disclose the risk that CVS Caremark's rigid formulary system could push a neffy coverage decisio...
AARP issues urgent call on Medicare drug costs
American seniors pay dramatically more for brand-name prescription drugs than patients in 19 comparable countries, and the gap keeps widening each year. AARP...
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Mineralys Therapeutics, Inc.'s Q2 2026 earnings call
Heron Therapeutics Q2 Earnings Call Highlights
Heron Therapeutics (NASDAQ:HRTX) reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the co...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
Wall Street called the missed CVS Caremark formulary date a "negative shock" — a securities class action alleges ARS Pharmaceuticals built analyst expectatio...
Collegium Pharmaceutical Q2 Earnings Call Highlights
Collegium Pharmaceutical (NASDAQ:COLL) reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD f...
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-universal payer coverage expands market access Initial cutaneou...
The Signs Before Eli Lilly Stock Surged Were All On The Record
Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.